Unveiling the etiological impact of GST-M1, GST-T1, and P53 genotypic variations on brain carcinogenesis
© 2023. The Author(s), under exclusive licence to Springer Nature B.V..
BACKGROUND: Functional variants of glutathione-S-transferase (GST)-M1, GST-T1, p53 might modulate brain cancer risk by altering the rate of metabolism and clearance of carcinogens from the brain tissue. In this study, the role of GST-M1, GST-T1, p53 polymorphisms on brain tumor was investigated.
METHODS AND RESULTS: Brain tumor tissues of 143 patients were obtained from the Gulhane Training and Research Hospital, Department of Neurosurgery between 2019 and 2020. In the xenobiotic mechanism, the null allele frequency in the GST-T1, GST-M1 gene regions of Phase II enzymes by qPCR method were investigated. Single nucleotide polymorphism encoding Arg/Pro conversion in the p53 gene region was analyzed in 120 cases by sequence analysis method. The data were analyzed statistically with patient's demographic and clinical data. GST-M1, GST-T1, p53 genotypes of the patient group were determined. The most frequent genotype was null genotype (0/0) for GST-M1 (χ2 = 39.756, p < 0.001). GST-M1 genotype frequencies were 30.8%, 23.1%, 44.3% for 1/1, 1/0, 0/0, respectively. The most frequent genotype was GST-T1 1/1 following by GST-T1 1/0 (χ2 = 0.335, p = 0.846). GST-T1 genotype frequencies were 64.3%, 30.8%, 4.9% for 1/1, 1/0, 0/0, respectively. GST-M1 null genotype might be associated with the development of brain tumors. Genotype distribution obtained in p53 exon 4 codon 72; Arg/Arg was determined as 31 (25.8%), Arg/Pro 70 (58.3%), and Pro/Pro 19 (15.8%) in the case group, while there were 18 (38.3%), 23 (48.9%), and 6 (12.8%) respectively in the control group. However, the genotype distribution of p53 exon 4 codon 72 among tumorous tissue did not significantly vary from healthy control tissues (χ²=2.536, p = 0.281).
CONCLUSION: The null allele frequency encountered in the GST-M1, GST-T1 gene regions is consistent with the rates in the gene pool called Caucasian in the literature. GST-M1 gene polymorphism may play a crucial role in brain carcinogenesis in Turkish patients. This study based on clinical data is thought to help to understand the important epidemiological features of brain tumors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Molecular biology reports - 51(2023), 1 vom: 29. Dez., Seite 45 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dirican, Onur [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Brain tumors |
|---|
| Anmerkungen: |
Date Completed 03.01.2024 Date Revised 03.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11033-023-08985-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366490761 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366490761 | ||
| 003 | DE-627 | ||
| 005 | 20240108141331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11033-023-08985-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1247.xml |
| 035 | |a (DE-627)NLM366490761 | ||
| 035 | |a (NLM)38158432 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dirican, Onur |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Unveiling the etiological impact of GST-M1, GST-T1, and P53 genotypic variations on brain carcinogenesis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2024 | ||
| 500 | |a Date Revised 03.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature B.V. | ||
| 520 | |a BACKGROUND: Functional variants of glutathione-S-transferase (GST)-M1, GST-T1, p53 might modulate brain cancer risk by altering the rate of metabolism and clearance of carcinogens from the brain tissue. In this study, the role of GST-M1, GST-T1, p53 polymorphisms on brain tumor was investigated | ||
| 520 | |a METHODS AND RESULTS: Brain tumor tissues of 143 patients were obtained from the Gulhane Training and Research Hospital, Department of Neurosurgery between 2019 and 2020. In the xenobiotic mechanism, the null allele frequency in the GST-T1, GST-M1 gene regions of Phase II enzymes by qPCR method were investigated. Single nucleotide polymorphism encoding Arg/Pro conversion in the p53 gene region was analyzed in 120 cases by sequence analysis method. The data were analyzed statistically with patient's demographic and clinical data. GST-M1, GST-T1, p53 genotypes of the patient group were determined. The most frequent genotype was null genotype (0/0) for GST-M1 (χ2 = 39.756, p < 0.001). GST-M1 genotype frequencies were 30.8%, 23.1%, 44.3% for 1/1, 1/0, 0/0, respectively. The most frequent genotype was GST-T1 1/1 following by GST-T1 1/0 (χ2 = 0.335, p = 0.846). GST-T1 genotype frequencies were 64.3%, 30.8%, 4.9% for 1/1, 1/0, 0/0, respectively. GST-M1 null genotype might be associated with the development of brain tumors. Genotype distribution obtained in p53 exon 4 codon 72; Arg/Arg was determined as 31 (25.8%), Arg/Pro 70 (58.3%), and Pro/Pro 19 (15.8%) in the case group, while there were 18 (38.3%), 23 (48.9%), and 6 (12.8%) respectively in the control group. However, the genotype distribution of p53 exon 4 codon 72 among tumorous tissue did not significantly vary from healthy control tissues (χ²=2.536, p = 0.281) | ||
| 520 | |a CONCLUSION: The null allele frequency encountered in the GST-M1, GST-T1 gene regions is consistent with the rates in the gene pool called Caucasian in the literature. GST-M1 gene polymorphism may play a crucial role in brain carcinogenesis in Turkish patients. This study based on clinical data is thought to help to understand the important epidemiological features of brain tumors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Brain tumors | |
| 650 | 4 | |a GST-M1 | |
| 650 | 4 | |a GST-T1 | |
| 650 | 4 | |a Polymorphism | |
| 650 | 4 | |a p53 | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a Glutathione Transferase |2 NLM | |
| 650 | 7 | |a EC 2.5.1.18 |2 NLM | |
| 650 | 7 | |a Codon |2 NLM | |
| 700 | 1 | |a Kaygın, Pınar |e verfasserin |4 aut | |
| 700 | 1 | |a Oğuztüzün, Serpil |e verfasserin |4 aut | |
| 700 | 1 | |a Husseini, Abbas Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Sarıaltın, Sezen Yılmaz |e verfasserin |4 aut | |
| 700 | 1 | |a Yılmaz, Can |e verfasserin |4 aut | |
| 700 | 1 | |a Ünlü, Nihan |e verfasserin |4 aut | |
| 700 | 1 | |a İzci, Yusuf |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular biology reports |d 1973 |g 51(2023), 1 vom: 29. Dez., Seite 45 |w (DE-627)NLM000008168 |x 1573-4978 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2023 |g number:1 |g day:29 |g month:12 |g pages:45 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11033-023-08985-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2023 |e 1 |b 29 |c 12 |h 45 | ||